Their price target is currently $0.67/share. This is derived from a 50% chance that Cynata's aGvHD therapy is successful (i.e. if it is successful it is worth $1.33/share). It is notable that no value has been ascribed in this research report for:
Knee Osteoarthritis (Phase 3 trial enrolment complete, results due in 12-15 months). US$11.6Bn TAM
Renal Transplantation (Phase 1 trial underway. Cohort A results due this quarter). US$5.9Bn TAM
Diabetic Foot Ulcers (Phase 1 trial complete; no safety concerns and clear evidence of wound reduction when using CYPatch). US$9.6Bn TAM
Other indications which Cynata has preclinical data for including ARDS, Sepsis, Asthma, IPF, CLI etc.
Please ask as many questions as you need and someone will do their best to answer them for you.
CYP Price at posting:
22.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)